Condition: Tenosynovial Giant Cell Tumor · Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
The primary purpose of this study is to assess the tolerability, pharmacokinetics, and efficacy of pimicotinib in Japanese participants with TGCT
This description comes directly from the study's public registry record.
Communication Center · +49 6151 72 5200 · service@emdgroup.com
Always discuss trial participation with your own doctor first.
| National Cancer Center Hospital | Chūōku, Japan | Recruiting |
| Kyushu University Hospital - 300173484 | Fukuoka, Japan | Recruiting |
| Nagoya University Hospital - 300176284 | Nagoya, Japan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07499362